{"id":144534,"date":"2010-01-06T09:36:16","date_gmt":"2010-01-06T14:36:16","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=57342"},"modified":"2010-01-06T09:36:16","modified_gmt":"2010-01-06T14:36:16","slug":"combinatorx-names-new-ceo","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/144534","title":{"rendered":"CombinatoRx Names New CEO"},"content":{"rendered":"\n
Biotech<\/a>, people<\/a>, Drugs<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

Cambridge, MA-based CombinatoRx (NASDAQ: CRXX<\/a>) said today<\/a> it has named Mark Corrigan as its new CEO, following the merger with NeuroMed Pharmaceuticals. Corrigan, 52, is the former executive vice president of R&D at Sepracor and a director of CombinatoRx. He will be paid an annual base salary of $450,000, may get a bonus worth half his base salary, and could get restricted stock units worth as much as 3 percent of the company’s market capitalization if CombinatoRx’s lead pain drug wins FDA approval by October 1, according to a regulatory filing<\/a>. Robert Forrester, the former chief operating officer, is leaving the company, while NeuroMed’s former CEO, Christopher Gallen, will stay as executive vice president of R&D.<\/p>\n

Comments (1)<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, people, Drugs Luke Timmerman wrote: Cambridge, MA-based CombinatoRx (NASDAQ: CRXX) said today it has named Mark Corrigan as its new CEO, following the merger with NeuroMed Pharmaceuticals. Corrigan, 52, is the former executive vice president of R&D at Sepracor and a director of CombinatoRx. He will be paid an annual base salary of $450,000, […]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-144534","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/144534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=144534"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/144534\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=144534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=144534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=144534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}